Trials / Completed
CompletedNCT05317741
SAD Study of IA-14069
A Phase 1, First-in-human, Double-Blind, Placebo-Controlled, Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Food Effect, and Pharmacodynamics Following a Single Oral Dose of IA-14069 in Healthy Male Subjects
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 40 (actual)
- Sponsor
- ILAb Co., Ltd. · Industry
- Sex
- Male
- Age
- 18 Years – 55 Years
- Healthy volunteers
- Accepted
Summary
The purpose of this study is to assess the safety, tolerability, pharmacokinetics, food effect, and pharmacodynamics following a single oral dose of IA-14069 in healthy male subjects.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | IA-14069 | Subjects received IA-14069 tablet orally on Day 1. |
| DRUG | Placebo | Subjects received matching placebo tablet orally on Day 1. |
Timeline
- Start date
- 2021-08-23
- Primary completion
- 2022-09-08
- Completion
- 2022-09-08
- First posted
- 2022-04-08
- Last updated
- 2023-01-04
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05317741. Inclusion in this directory is not an endorsement.